| Date Filed | Type | Description |
| 10/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 10.5% stake in ANGIODYNAMICS INC |
| 10/05/2023 |
10-Q
| Quarterly Report for the period ended August 31, 2023 |
| 10/04/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/03/2023 |
10-K
| Annual Report for the period ended May 31, 2023 |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
SC 13G/A
| VICTORY CAPITAL MANAGEMENT INC reports a 3.7% stake in Angiodynamics Inc. |
| 06/08/2023 |
8-K
| Asset disposition|
Docs:
|
"Latham, New York, June 8, 2023 – AngioDynamics, Inc. , a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it has completed the sale of its Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product to Merit Medical Systems, Inc. for $100 million in cash. The transaction consists of AngioDynamics’ DuraFlow™, DuraMax ® , Evenmore ® , Schon XL ® , Trio-CT ® and Vaxel Plus Hemodialysis Catheter brands, and BioSentry™ Tract Sealant System Biopsy brand. This combined portfolio of products contributed approximately $32 million in sales in AngioDynamics’ Fiscal Year 2023. AngioDynamics intends t..." |
|
| 06/02/2023 |
8-K
| Other Events Interactive Data |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
10-Q
| Quarterly Report for the period ended February 28, 2023 |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/27/2023 |
8-K
| Other Events Interactive Data |
| 02/10/2023 |
SC 13G/A
| DIMENSIONAL FUND ADVISORS LP reports a 6.9% stake in AngioDynamics Inc |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 7.1% stake in AngioDynamics Inc. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G/A
| STATE STREET CORP reports a 5.1% stake in AMENDED FILING ANGIODYNAMICS INC |
| 01/31/2023 |
SC 13G/A
| VICTORY CAPITAL MANAGEMENT INC reports a 10.9% stake in Angiodynamics Inc. |
| 01/20/2023 |
SC 13G/A
| BlackRock Inc. reports a 17.2% stake in ANGIODYNAMICS INC |
| 01/12/2023 |
8-K
| Quarterly results |
| 01/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/06/2023 |
10-Q
| Quarterly Report for the period ended November 30, 2022 |
| 01/05/2023 |
8-K
| Quarterly results |
| 12/15/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
8-K
| Quarterly results |
| 10/12/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/11/2022 |
10-Q
| Quarterly Report for the period ended August 31, 2022 |
| 10/06/2022 |
8-K
| Quarterly results |
| 10/06/2022 |
8-K
| Quarterly results |
|